David Tordrup

Economic burden of female genital mutilation in 27 high-prevalence countries David Tordrup1,2, Chrissy Bishop3, Nathan Green4, Max Petzold5, Fernando Ruiz Vallejo6, http://orcid.org/0000-0002-3214-7096Joshua P Vogel7, http://orcid.org/0000-0002-7779-9303Christina Pallitto8 1 WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Utrecht, The Netherlands 2 Triangulate Health Ltd, Doncaster, UK 3 Independent Consultant, London, UK 4 University College London, London, UK 5 School of...

Summary Background To address the growing prevalence of hearing loss, WHO has identified a compendium of key evidence-based ear and hearing care interventions to be included within countries’ universal health coverage packages. To assess the cost-effectiveness of these interventions and their budgetary effect for countries, we aimed to analyse the investment required to scale up services from baseline to recommended levels, and the return to society for every US$1 invested in the compendium.

Summary Background The World Health Assembly calls for elimination of viral hepatitis as a public health threat by 2030 (ie, −90% incidence and −65% mortality). However, WHO's 2017 cost projections to achieve health-related Sustainable Development Goals did not include the resources needed for hepatitis testing and treatment. We aimed to estimate the incremental commodity cost of adding scaled up interventions for testing and treatment of hepatitis to WHO's investment scenarios.